‘Remarkable’ gene-editing treatment for sickle cell disease is approved by FDA

The FDA has approved the world’s first gene-edited treatment for symptoms of sickle cell disease. Experts weigh in on the potential benefits and limitations.

"CASGEVY’s approval by the FDA is momentous," Reshma Kewalramani, M.D., chief executive officer and president of Vertex Pharmaceuticals in Boston, said in a statement provided to Fox News Digital. "CASGEVY is a first-in-class treatment that offers the potential of a one-time transformative therapy for eligible patients with sickle cell disease."

"It is the first CRISPR-based gene-editing therapy to be approved in the U.S."